Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19
CONCLUSION AND RELEVANCE: Approximately 52% of patients on warfarin were eligible for DOACs. This presents an opportunity to reduce patient exposure to health care settings and health care utilization in the setting of COVID-19. Increased costs of DOACs need to be assessed.PMID:36373362 | DOI:10.1177/10600280221136874
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Rachel Hess Elizabeth Renner Erin Mouland Denise Sutter-Long Nghi Ha Source Type: research
More News: Atrial Fibrillation | Coumadin | COVID-19 | Drugs & Pharmacology | Health Management | Pradaxa | Stroke | Study | Thrombosis | Warfarin